Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MEDNAX (MD) stocks in Canada

Learn how to easily invest in MEDNAX stocks.

- $0.06 ( - 0.24%)

MEDNAX is a medical care facilities business based in the US. MEDNAX stocks (MD.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $29.21 – a decrease of 7.06% over the previous week. MEDNAX employs 5,600 staff and has a trailing 12-month revenue of around $1.8 billion.

How to buy shares in MEDNAX

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MEDNAX stock price (NYSE:MD)

Use our graph to track the performance of MD stocks over time.

MEDNAX shares at a glance

Information last updated 2022-01-18.
Latest market close$25.01
52-week range$20.27 - $35.67
50-day moving average $26.65
200-day moving average $28.83
Wall St. target price$27.10
PE ratio 116.4935
Dividend yield N/A (0%)
Earnings per share (TTM) $0.23

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy MEDNAX stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

MEDNAX price performance over time

Historical closes compared with the close of $25.01 from 2022-01-20

1 week (2022-01-11) -7.23%
1 month (2021-12-17) N/A
3 months (2021-10-20) -6.12%
6 months (2021-07-21) -15.39%
1 year (2021-01-21) 2.12%
2 years (2020-01-21) -7.85%
3 years (2019-01-18) 36.79
5 years (2017-01-20) 70.05

Is MEDNAX under- or over-valued?

Valuing MEDNAX stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEDNAX's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MEDNAX's P/E ratio

MEDNAX's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 116x. In other words, MEDNAX shares trade at around 116x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

MEDNAX's PEG ratio

MEDNAX's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.88. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEDNAX's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.


MEDNAX's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $223.9 million.

The EBITDA is a measure of a MEDNAX's overall financial performance and is widely used to measure a its profitability.

MEDNAX financials

Revenue TTM $1.8 billion
Operating margin TTM 10.49%
Gross profit TTM $449.3 million
Return on assets TTM 3.95%
Return on equity TTM 8.75%
Profit margin 1.05%
Book value $9.92
Market capitalisation $2.3 billion

TTM: trailing 12 months

MEDNAX's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like MEDNAX.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

MEDNAX's total ESG risk score

Total ESG risk: 19.73

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and MEDNAX's overall score of 19.73 (as at 01/01/2019) is pretty good – landing it in it in the 22nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like MEDNAX is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

MEDNAX's environmental score

Environmental score: 1.84/100

MEDNAX's environmental score of 1.84 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that MEDNAX is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

MEDNAX's social score

Social score: 8.57/100

MEDNAX's social score of 8.57 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that MEDNAX is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

MEDNAX's governance score

Governance score: 5.5/100

MEDNAX's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that MEDNAX is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

MEDNAX's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. MEDNAX scored a 1 out of 5 for controversy – the highest score possible, reflecting that MEDNAX has managed to keep its nose clean.

MEDNAX share dividends

We're not expecting MEDNAX to pay a dividend over the next 12 months.

Have MEDNAX's shares ever split?

MEDNAX's shares were split on a 2:1 basis on 20 December 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your MEDNAX shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for MEDNAX shares which in turn could have impacted MEDNAX's share price.

MEDNAX share price volatility

Over the last 12 months, MEDNAX's shares have ranged in value from as little as $20.2701 up to $35.67. A popular way to gauge a stock's volatility is its "beta".

MD.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while MEDNAX's is 2.1049. This would suggest that MEDNAX's shares are significantly more volatile than the average for this exchange and represent a higher risk.

MEDNAX overview

MEDNAX, Inc. , together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of March 16, 2021, it operated a network of approximately 2,300 physicians.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site